About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia.
Company Fact Sheet
Company Overview Video
Press Room
About Restanza
Restanza is a novel, once-a-day, oral antibiotic that is in late stage development for the treatment of life threatening infections including CABP and biodefense pathogens. Restanza has demonstrated in clinical trials an ability to overcome bacterial resistance. The FDA has designated Restanza as an orphan drug for anthrax, plague and tularemia, but the drug is not yet approved for these or any indications.
Company Fact Sheet
Company Overview Video